19Aug
18Aug
Cannabis and Science
In the 1980s and 1990s, researchers identified cannabinoid receptors in humans (CB1 for THC and CB2 for CBD). What they were uncovering was the human body’s own endocannabinoid system (ECS). “It’s a system as ancient as our immune system and our central nervous system. They co-evolved and our endocannabinoid system acts as a bridge between the two,” says Yuval Cohen, CEO and Director of Corbus Pharmaceuticals. Read more >>
18Aug
2020 International Canned Wine Competition
The dust has settled and the results are in for the second annual International Canned Wine Competition. Completion of the contest was delayed as more than forty entries were held up in U.S. Customs for reasons known only to Customs clerks, but now all results are in. Archer Roose included on list. Read more >>
14Aug
Kalion Inc. Receives NSF Phase II SBIR Grant to Develop Bio-based Glucaric Acid
Kalion Inc. has been awarded a National Science Foundation (NSF) Phase II Small Business Research (SBIR) grant for $746,822 to conduct research and development work improving the bio-based production of glucaric acid. Glucaric acid and its related compounds enhance sustainability as well as improve the chemical properties of products ranging from water treatment, polymers & textiles, coatings, detergents and pharmaceuticals. Read more >>
11Aug
eSight 4 Earns CE Mark Approval to Bring New Wearable Device to Europe
eSight, a cutting-edge vision enhancement platform, today announces it has received CE Mark approval for eSight 4, the company's latest assistive technology device that's clinically proven to significantly enhance vision for those living with low vision and legal blindness. The CE Mark certification signifies that eSight 4 has been assessed to meet high safety, health and environmental protection requirements in Europe and is considered an essential requirement for companies to sell and distribute medical products within the European Economic Area...
07Aug
Corbus Pharmaceuticals Reports Second Quarter Financial Results and Corporate Updates
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today reported financial results for the second quarter of 2020. The Company also provided clinical and corporate updates. Read more >>
06Aug
Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the completion of subject enrollment in DETERMINE, a Phase 3 study assessing the efficacy and safety of lenabasum for the treatment of dermatomyositis. Read more >>
05Aug
LaunchPad Medical Rebrands as RevBio and Launches an Updated Website
Executives from LaunchPad Medical, Inc. announced that the company has rebranded. Its new name, RevBio, was chosen since it more accurately portrays the objective of developing its revolutionary Tetranite® bone adhesive biomaterial platform. Read more >>
04Aug
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present at two upcoming conferences. Read more >>
29Jul